Gabriella Bröms, MD, PhD
Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Internal Medicine, Danderyd Hospital, Stockholm, Sweden; Corresponding author: Gabriella Bröms, MD, PhD, Centre for Pharmacoepidemiology, Department of Medicine Solna,
Original Research
Atomoxetine and Prevalence of Major Congenital Malformations
January 16, 2023
Little is known about the safety of atomoxetine, a non-stimulant treatment for attention-deficit/hyperactivity disorder. This study assessed the prevalence of major congenital malformations after first-trimester exposure to atomoxetine.